Related Experiment Video
Updated: Jun 17, 2026
Analysis of Learning and Memory Ability in an Alzheimer's Disease Mouse Model using the Morris Water Maze
Published on: October 29, 2019
Effects of the endogenous PPAR-alpha agonist, oleoylethanolamide on MDMA-induced cognitive deficits in mice
Ainhoa Plaza-Zabala1, Fernando Berrendero, Juan Suarez
1Laboratori de Neurofarmacologia, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, 08003Barcelona, Spain.
Abstract:
MDMA (3,4-Methylenedioxymethamphetamine) is an amphetamine derivative widely used for recreational purposes. We have recently shown that repeated treatment with high doses of MDMA-induced impairments in the acquisition and recall of an active avoidance task in mice. In this study, we examined whether the endogenous peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, oleoylethanolamide (OEA) protects against these MDMA-induced deficits. Mice were pretreated twice a day with OEA (0, 5, and 25 mg/kg) 30 min before an injection of MDMA (30 mg/kg) or saline during four consecutive days. Twenty-four hours after the last treatment, animals were trained in an active avoidance task for two consecutive weeks. After a 5-day resting period, a recall session was performed. Mice treated with MDMA showed reduced learning and recall of the task when compared with saline-treated controls. OEA at 5 mg/kg ameliorated and at 25 mg/kg worsened this deficit. Dopamine transporter (DAT)-binding sites significantly decreased 4 days after the last MDMA administration and pretreatment with both doses of OEA prevented this effect. In immunohistochemical studies, coexpression of tyrosine-hydroxylase and PPAR-alpha receptors was observed in the striatum and substantia nigra pars compacta of mice. These results suggest that OEA administration can modulate the cognitive deficits induced by MDMA in a DAT-independent manner.
Insights
Oleoylethanolamide (OEA) was investigated for its effects on cognitive deficits induced by 3,4-Methylenedioxymethamphetamine (MDMA) in mice. OEA showed a dose-dependent effect, ameliorating some deficits while worsening others, suggesting a complex interaction.
Area of Science:
- Neuroscience
- Pharmacology
- Behavioral Science
Background:
- 3,4-Methylenedioxymethamphetamine (MDMA) is a recreational drug known to cause cognitive impairments.
- Previous research indicated MDMA-induced deficits in active avoidance learning and recall in mice.
- Peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonists are endogenous compounds with potential neuroprotective roles.
Purpose of the Study:
- To investigate the neuroprotective potential of oleoylethanolamide (OEA), an endogenous PPAR-alpha agonist, against MDMA-induced cognitive deficits.
- To determine the effect of OEA pretreatment on MDMA-induced impairments in active avoidance learning and recall.
- To explore the impact of OEA on dopamine transporter (DAT) binding sites and receptor coexpression following MDMA exposure.
Main Methods:
- Mice were pretreated with varying doses of OEA (0, 5, 25 mg/kg) before MDMA (30 mg/kg) or saline administration over four days.
- Cognitive function was assessed using an active avoidance task, including acquisition and recall phases.
- Dopamine transporter (DAT) binding and immunohistochemical coexpression of tyrosine-hydroxylase and PPAR-alpha were analyzed.
Main Results:
- MDMA treatment significantly impaired learning and recall in the active avoidance task compared to controls.
- OEA at 5 mg/kg ameliorated MDMA-induced cognitive deficits, while 25 mg/kg worsened them.
- MDMA decreased DAT-binding sites, an effect prevented by OEA pretreatment; coexpression of tyrosine-hydroxylase and PPAR-alpha was observed in specific brain regions.
Conclusions:
- Oleoylethanolamide (OEA) exhibits a dose-dependent and complex modulatory effect on MDMA-induced cognitive deficits.
- OEA's protective effects against MDMA-induced changes in DAT binding sites appear to be independent of its impact on cognitive recall.
- The findings suggest OEA's potential role in modulating neurochemical pathways affected by MDMA, warranting further investigation.
